Daiichi and AstraZeneca fight back in cancer drug dispute with Seagen

Daiichi Sankyo and AstraZeneca have asked the US District Court for the District of Delaware for a declaration that their breast cancer treatment does not infringe a chemotherapy patent owned by biotechnology company Seagen.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

AstraZeneca to buy Alexion for $39bn

14 December 2020 AstraZeneca has announced it will acquire Boston-based biopharmaceutical company Alexion Pharmaceuticals, in what is potentially the biggest life sciences deal of this year.

Americas

Pyxis secures ADC licence from Pfizer

22 March 2021 Massachusetts-based biotechnology start-up Pyxis Oncology has secured a licensing deal with Pfizer for two of the pharmaceutical giant’s antibody-drug conjugates.

Big Pharma

PTAB grants review of Seagen patent on eve of court’s infringement ruling

11 April 2022 The US Patent Trial and Appeal Board has agreed to review claims of a Seagen patent that Daiichi Sankyo was found to have infringed with its Enhertu breast cancer treatment.

More on this story

Americas

AstraZeneca to buy Alexion for $39bn

14 December 2020 AstraZeneca has announced it will acquire Boston-based biopharmaceutical company Alexion Pharmaceuticals, in what is potentially the biggest life sciences deal of this year.

Americas

Pyxis secures ADC licence from Pfizer

22 March 2021 Massachusetts-based biotechnology start-up Pyxis Oncology has secured a licensing deal with Pfizer for two of the pharmaceutical giant’s antibody-drug conjugates.

Big Pharma

PTAB grants review of Seagen patent on eve of court’s infringement ruling

11 April 2022 The US Patent Trial and Appeal Board has agreed to review claims of a Seagen patent that Daiichi Sankyo was found to have infringed with its Enhertu breast cancer treatment.

More on this story

Americas

AstraZeneca to buy Alexion for $39bn

14 December 2020 AstraZeneca has announced it will acquire Boston-based biopharmaceutical company Alexion Pharmaceuticals, in what is potentially the biggest life sciences deal of this year.

Americas

Pyxis secures ADC licence from Pfizer

22 March 2021 Massachusetts-based biotechnology start-up Pyxis Oncology has secured a licensing deal with Pfizer for two of the pharmaceutical giant’s antibody-drug conjugates.

Big Pharma

PTAB grants review of Seagen patent on eve of court’s infringement ruling

11 April 2022 The US Patent Trial and Appeal Board has agreed to review claims of a Seagen patent that Daiichi Sankyo was found to have infringed with its Enhertu breast cancer treatment.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

Daiichi and AstraZeneca fight back in cancer drug dispute with Seagen

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features